There is no national shortage of Ozempic, Wegovy, Mounjaro or Zepbound in FDA's records. The one GLP-1 molecule still listed is liraglutide, the older daily drug sold as Victoza and Saxenda, which has been on FDA's list since July 2023. The semaglutide and tirzepatide shortages that drove the compounding boom were declared over in December 2024 and February 2025.
This page reads FDA's drug-shortage data through its public openFDA interface on 2 November 2026 (dataset last updated 30 October 2026), and FDA's own statement on how the resolved shortages ended. It is a dated register. A shortage entry is about national supply; it says nothing about whether one pharmacy has a pen in stock today.
The register on 2 November 2026
| Molecule (brands) | Records in FDA's shortage data | Status | What the records say |
|---|---|---|---|
| Liraglutide (Victoza, Saxenda, generics) | 11 | 9 Current · 2 To Be Discontinued | first posted 18 July 2023; Victoza and Saxenda "Limited Availability"; six generic packs "Available" |
| Semaglutide injection (Ozempic, Wegovy) | 0 | — | shortage resolved 21 February 2025 |
| Semaglutide tablets (Rybelsus) | 3 | To Be Discontinued | 3, 7 and 14 mg, dated 4 June 2026; to be replaced by Ozempic tablets |
| Tirzepatide (Mounjaro, Zepbound) | 0 | — | shortage resolved 19 December 2024 |
| Dulaglutide (Trulicity) | 0 | — | no record |
| Exenatide | 0 | — | no record |
Source: openFDA drug shortages endpoint, queried by generic name. openFDA states its data are "unvalidated" and should not be relied on for medical decisions; FDA's own Drug Shortages database is the authoritative listing.
Liraglutide, pack by pack
Every liraglutide pack in the data is the same strength, 6 mg/mL in a 3 mL pen. What differs is the label it is sold under and its supply status:
| Pack | Company | Status | Availability | Reason or note | Last updated |
|---|---|---|---|---|---|
| Victoza (NDC 0169-4060-12) | Novo Nordisk | Current | Limited | "Delay in shipping of the drug"; duration "TBD" | 22 Sep 2026 |
| Victoza (NDC 0169-4060-13) | Novo Nordisk | Current | Limited | same | 22 Sep 2026 |
| Saxenda (NDC 0169-2800-15) | Novo Nordisk | Current | Limited | manufacture discontinued; available "until discontinuation in January 2027" | 22 Sep 2026 |
| Saxenda (same NDC) | Novo Nordisk | To Be Discontinued | — | posted 25 Aug 2026 | 25 Aug 2026 |
| Liraglutide (NDC 0480-3667-20, -22) | Novo Nordisk, "Distributed by Teva" | Current | Available | — | 22 Sep 2026 |
| Liraglutide (NDC 0143-9144-02, -03) | Hikma | Current | Available | — | 14 Oct 2026 |
| Liraglutide (NDC 71288-563-84, -85) | Meitheal | Current | Available | — | 27 Aug 2026 |
| Liraglutide (NDC 0480-7250-46) | Teva | To Be Discontinued | — | manufacture discontinued, posted 14 May 2026 | 14 May 2026 |
The pattern is that the brand packs are the scarce ones. The generic packs are listed as available while staying under the same 2023 shortage entry. Which generics substitute for Victoza and which for Saxenda is a separate question, answered by FDA's equivalence codes on the Saxenda and Victoza pages. An "Available" generic is not automatically a substitute for both brands.
How the semaglutide and tirzepatide shortages ended
FDA's page on compounding as supply stabilised (content current as of 1 April 2026) gives both timelines. Both shortages began in 2022, "due to increased demand".
| Tirzepatide | Semaglutide | |
|---|---|---|
| Shortage declared resolved | 19 December 2024 (reaffirming a 2 October 2024 decision after re-evaluation) | 21 February 2025 |
| Enforcement discretion ended, 503A state-licensed pharmacies | 18 February 2025 (held pending litigation; ended after a court denied a preliminary injunction on 5 March 2025) | 22 April 2025 (held pending litigation; ended after a court denied a preliminary injunction on 24 April 2025) |
| Enforcement discretion ended, 503B outsourcing facilities | 19 March 2025 | 22 May 2025 |
Why those dates still matter. While a drug is on FDA's shortage list, compounders may make copies of it under rules that otherwise forbid "essentially copies" of an approved drug. The end of the shortage closed that route. What compounding is still sold, and on what legal footing, is on compounded semaglutide and compounded tirzepatide vs Zepbound.
Two discontinuations that are not shortages
- Rybelsus 3, 7 and 14 mg. FDA's data list all three as "To Be Discontinued", posted 4 June 2026, with the note: "These products will be replaced by Ozempic (semaglutide) tablets." The Rybelsus label reports "no clinically significant differences" in steady-state exposure between 3, 7 and 14 mg of Rybelsus and 1.5, 4 and 9 mg of Ozempic tablets in healthy subjects, and states that the two "are not substitutable on a mg-to-mg basis". The oral products are compared on the Ozempic pill.
- Saxenda. Novo Nordisk has notified FDA that the pack will be discontinued, available "until discontinuation in January 2027". Generic liraglutide rated equivalent to Saxenda exists; see Saxenda vs Zepbound and the Saxenda page.
A discontinuation entry means the maker has told FDA it will stop making that product. It is not a statement that the molecule will be unavailable.
What the register cannot tell anyone
- Local stock. A pharmacy can be out of one strength on one day without any national shortage. FDA's list tracks national supply.
- Insurance or price. A drug that is not in shortage can still be unaffordable or not covered; those questions are on GLP-1 cost and how to get a GLP-1.
- Future shortages. The records show the present and the past. They do not forecast supply.
Sources
- openFDA drug shortages endpoint, queried 2 November 2026 for semaglutide, tirzepatide, liraglutide, dulaglutide and exenatide (dataset last updated 30 October 2026).
- FDA, "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize", content current as of 1 April 2026, read 2 November 2026: fda.gov.
- Rybelsus and Ozempic tablets US prescribing information (effective 30 January 2026), sections 2.1 and 12.3, read on DailyMed 2 November 2026.